{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:17:06Z","timestamp":1790180226312,"version":"4.1.0"},"reference-count":205,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cardfail.2017.04.014","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T00:32:51Z","timestamp":1493425971000},"page":"628-651","source":"Crossref","is-referenced-by-count":498,"title":["2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the\u00a0Management of Heart Failure"],"prefix":"10.1016","volume":"23","author":[{"given":"Clyde W.","family":"Yancy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariell","family":"Jessup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Donald E.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Colvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Drazner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos S.","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Givertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Hollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Masoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela N.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne Warner","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Westlake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2017.04.014_bib0010","series-title":"Clinical Practice Guidelines We Can Trust","year":"2011"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0015","series-title":"Finding What Works in Health Care: Standards for Systematic Reviews","year":"2011"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0020","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0025","series-title":"Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines","year":"2010"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0030","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jacc.2015.09.001","article-title":"Further evolution of the ACC\/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"67","author":"Halperin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2012.09.025","article-title":"ACCF\/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"Jacobs","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jacc.2014.06.001","article-title":"The evolution and future of ACC\/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"64","author":"Jacobs","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0045","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2014.07.012","volume":"64","author":"Arnett","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0050","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0055","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0060","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0070","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0075","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0080","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0735-1097(01)01269-4","article-title":"Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group","volume":"37","author":"Richards","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0085","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1161\/01.CIR.0000106903.98196.B6","article-title":"Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure","volume":"108","author":"Tang","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejheart.2005.01.022","article-title":"The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study","volume":"7","author":"Zaphiriou","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0095","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jbi.2012.04.013","article-title":"Decision-making model for early diagnosis of congestive heart failure using rough set and decision tree approaches","volume":"45","author":"Son","year":"2012","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0100","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.111.019216","article-title":"The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure","volume":"124","author":"Kelder","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0105","unstructured":"Balion C, Don-Wauchope A, Hill S, et al. Use of Natriuretic Peptide Measurement in the Management of Heart Failure [Internet]. 13(14)-EHC118-EF ed. Rockville, MD: 2013."},{"key":"10.1016\/j.cardfail.2017.04.014_bib0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10741-014-9445-8","article-title":"Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review","volume":"19","author":"Booth","year":"2014","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0735-1097(00)01156-6","article-title":"Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting","volume":"37","author":"Dao","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0140-6736(94)92690-5","article-title":"Plasma brain natriuretic peptide in assessment of acute dyspnoea","volume":"343","author":"Davis","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0130","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/CIRCULATIONAHA.106.666255","article-title":"N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study","volume":"115","author":"Moe","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa031681","article-title":"Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea","volume":"350","author":"Mueller","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.amjcard.2006.02.043","article-title":"Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure","volume":"98","author":"van Kimmenade","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2007.11.017","article-title":"Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms","volume":"101","author":"Januzzi","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10741-014-9444-9","article-title":"Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review","volume":"19","author":"Santaguida","year":"2014","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10741-014-9447-6","article-title":"Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence","volume":"19","author":"Hill","year":"2014","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2005.09.025","article-title":"Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction","volume":"47","author":"Costello-Boerrigter","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0165","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ahj.2008.12.017","article-title":"Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study","volume":"157","author":"de Lemos","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0170","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1093\/eurheartj\/ehl406","article-title":"Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction","volume":"27","author":"Goetze","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0175","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2004.12.058","article-title":"Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides","volume":"45","author":"Ng","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0180","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0185","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","article-title":"Prognostic utility of novel biomarkers of cardiovascular stress: the\u00a0Framingham Heart Study","volume":"126","author":"Wang","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0190","doi-asserted-by":"crossref","first-page":"e000399","DOI":"10.1161\/JAHA.113.000399","article-title":"Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening","volume":"2","author":"Xanthakis","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacc.2005.08.051","article-title":"Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study","volume":"47","author":"Anwaruddin","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0200","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(02)02059-4","article-title":"Plasma brain natriuretic peptide concentration: impact\u00a0of age and gender","volume":"40","author":"Redfield","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0002-9149(02)02464-5","article-title":"Impact of age and sex on plasma natriuretic peptide levels in healthy adults","volume":"90","author":"Wang","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2006.10.040","article-title":"Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study","volume":"49","author":"Chang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10741-011-9249-z","article-title":"The paradox of low BNP levels in obesity","volume":"17","author":"Clerico","year":"2012","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2459\/JCM.0b013e328364bde1","article-title":"B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis","volume":"15","author":"De Vecchis","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0225","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ahj.2009.06.018","article-title":"Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials","volume":"158","author":"Felker","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0230","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.hlc.2013.03.077","article-title":"B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials","volume":"22","author":"Li","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0235","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archinternmed.2010.35","article-title":"B-type natriuretic peptide-guided heart failure therapy: a meta-analysis","volume":"170","author":"Porapakkham","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0240","doi-asserted-by":"crossref","first-page":"e58287","DOI":"10.1371\/journal.pone.0058287","article-title":"Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials","volume":"8","author":"Savarese","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0245","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis","volume":"35","author":"Troughton","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-014-9437-8","article-title":"Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Xin","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0255","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2009.08.078","article-title":"N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study","volume":"55","author":"Berger","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0260","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","volume":"56","author":"Eurlings","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0265","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.cardfail.2012.05.005","article-title":"Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study","volume":"18","author":"Gaggin","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0270","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2006.10.081","article-title":"Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study","volume":"49","author":"Jourdain","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0275","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurjhf\/hfr078","article-title":"Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome","volume":"13","author":"Karlstrom","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0285","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/eurjhf\/hfq169","article-title":"Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure\u2013SIGNAL-HF (Swedish Intervention study\u2013Guidelines and NT-proBNP AnaLysis in Heart Failure)","volume":"12","author":"Persson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0290","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0295","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cardfail.2011.04.012","article-title":"The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure","volume":"17","author":"Shah","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0300","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations","volume":"355","author":"Troughton","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/CIRCHEARTFAILURE.108.826685","article-title":"Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management","volume":"2","author":"Singer","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2014.04.008","article-title":"Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes","volume":"168","author":"Stienen","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0315","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cardfail.2016.09.011","article-title":"PRIMA II: can NT-pro-brain-natriuretic peptide (NT-proBNP) guided therapy during admission for acute heart failure reduce mortality and readmissions?","volume":"22","author":"Stienen","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0320","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2010.06.016","article-title":"Troponin elevation in heart failure prevalence, mechanisms, and\u00a0clinical implications","volume":"56","author":"Kociol","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0325","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0330","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/CIRCULATIONAHA.111.044149","article-title":"Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials","volume":"125","author":"Masson","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0335","first-page":"148","article-title":"Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis","volume":"2","author":"Savarese","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0340","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2013.5809","article-title":"Increasingly sensitive assays for cardiac troponins: a review","volume":"309","author":"de Lemos","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0345","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ejhf.273","article-title":"State of the Art: Newer biomarkers in heart failure","volume":"17","author":"de Boer","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0350","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12265-013-9462-3","article-title":"New and emerging biomarkers in left ventricular systolic dysfunction\u2013insight into dilated\u00a0cardiomyopathy","volume":"6","author":"Gopal","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0355","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11897-013-0160-x","article-title":"Circulating biomarkers in patients with heart failure and preserved ejection fraction","volume":"10","author":"O'Meara","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0360","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11897-013-0169-1","article-title":"The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers","volume":"10","author":"Karayannis","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0365","first-page":"260","article-title":"Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure","volume":"2","author":"Ahmad","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0370","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0375","first-page":"65","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/CIRCHEARTFAILURE.111.965020","article-title":"Multiple biomarkers for risk prediction in chronic heart failure","volume":"5","author":"Ky","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0385","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/CIRCULATIONAHA.111.063842","article-title":"Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease","volume":"125","author":"Sabatine","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0390","first-page":"477","article-title":"Charting a roadmap for heart failure biomarker studies","volume":"2","author":"Ahmad","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0395","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/heartjnl-2011-300823","article-title":"Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure","volume":"98","author":"Miller","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0400","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0405","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ejhf.223","article-title":"Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction","volume":"17","author":"Wong","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0410","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ejhf.332","article-title":"Signature of circulating microRNAs in patients with acute heart failure","volume":"18","author":"Ovchinnikova","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0415","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.060368","article-title":"Metabolomic profiling for the identification of novel biomarkers and\u00a0mechanisms related to common cardiovascular diseases: form and function","volume":"126","author":"Shah","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0420","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2015.02.018","article-title":"Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics","volume":"65","author":"Cheng","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0425","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/aje\/kwt004","article-title":"Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study","volume":"178","author":"Zheng","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0430","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0435","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0440","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","article-title":"Changes in brain natriuretic peptide and norepinephrine over time\u00a0and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0445","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/01.CIR.0000016642.15031.34","article-title":"B-type natriuretic peptide predicts sudden death in patients\u00a0with chronic heart failure","volume":"105","author":"Berger","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0450","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2005.01.046","article-title":"Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit","volume":"45","author":"Forfia","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0455","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0735-1097(00)00912-8","article-title":"High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure","volume":"36","author":"Maeda","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0460","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jacc.2008.03.050","article-title":"Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease","volume":"52","author":"Neuhold","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0465","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.hfc.2008.11.009","article-title":"Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation","volume":"5","author":"Taub","year":"2009","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0470","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0475","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(00)01157-8","article-title":"A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study","volume":"37","author":"Cheng","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0480","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.amjcard.2007.07.066","article-title":"Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE","volume":"101","author":"Fonarow","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0485","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2003.09.044","article-title":"Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure","volume":"43","author":"Logeart","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0490","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2004.06.015","article-title":"Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath","volume":"44","author":"Maisel","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0495","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2008.12.017","article-title":"Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure","volume":"141","author":"Zairis","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0500","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Peacock","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0505","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7326\/0003-4819-156-11-201206050-00003","article-title":"Prediction of heart failure mortality in emergent care: a cohort study","volume":"156","author":"Lee","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0510","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10741-014-9442-y","article-title":"BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review","volume":"19","author":"Santaguida","year":"2014","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0515","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/01.CIR.0000084543.79097.34","article-title":"Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure","volume":"108","author":"Horwich","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0520","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ejheart.2008.06.009","article-title":"Clinical significance of cardiac troponins I and T in acute heart failure","volume":"10","author":"Ilva","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0525","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cardfail.2008.11.007","article-title":"Reduction in BNP levels with treatment of decompensated heart failure and future clinical events","volume":"15","author":"Dhaliwal","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0530","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2009.08.083","article-title":"Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score","volume":"55","author":"O'Connor","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0535","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1388-9842(03)00098-9","article-title":"Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF","volume":"5","author":"O'Brien","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0540","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jacc.2009.02.058","article-title":"Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure","volume":"53","author":"Cohen-Solal","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0545","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/heartjnl-2013-303632","article-title":"A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score","volume":"100","author":"Salah","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0550","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1161\/JAHA.114.000806","article-title":"B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes","volume":"3","author":"Flint","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0555","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCHEARTFAILURE.111.962290","article-title":"Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims","volume":"4","author":"Kociol","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0560","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCHEARTFAILURE.112.969246","article-title":"Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure","volume":"6","author":"Kociol","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0565","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2459\/JCM.0b013e3282f447ae","article-title":"NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients","volume":"9","author":"Verdiani","year":"2008","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0570","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.cardfail.2005.04.006","article-title":"NT-ProBNP reduction percentage during admission for\u00a0acutely decompensated heart failure predicts long-term cardiovascular mortality","volume":"11","author":"Bayes-Genis","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0575","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1388-9842(02)00021-1","article-title":"C-reactive protein as a predictor of improvement and readmission in heart failure","volume":"4","author":"Alonso-Martinez","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0580","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.clinbiochem.2010.02.002","article-title":"Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department","volume":"43","author":"Dieplinger","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0585","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0590","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjcard.2010.09.011","article-title":"Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction","volume":"107","author":"Manzano-Fernandez","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0595","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jacc.2008.07.042","article-title":"Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure","volume":"52","author":"Rehman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0600","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","article-title":"Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure","volume":"12","author":"Shah","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0605","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0610","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0615","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0620","first-page":"68","article-title":"Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure","volume":"4","author":"Tang","year":"2016","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0625","doi-asserted-by":"crossref","first-page":"26B","DOI":"10.1016\/j.amjcard.2015.01.037","article-title":"ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0630","doi-asserted-by":"crossref","first-page":"38B","DOI":"10.1016\/j.amjcard.2015.01.039","article-title":"ST2 and multimarker testing in acute decompensated heart failure","volume":"115","author":"Mebazaa","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0635","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3109\/1354750X.2012.719037","article-title":"Galectin 3 complements BNP in risk stratification in acute heart failure","volume":"17","author":"Fermann","year":"2012","journal-title":"Biomarkers"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0640","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ijcard.2013.01.228","article-title":"Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study","volume":"168","author":"Lassus","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0645","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0650","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0655","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0660","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0665","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0670","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0675","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0680","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0685","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0690","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0695","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0700","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0705","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0710","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0715","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0720","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0725","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","article-title":"Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"20","author":"Woodard-Grice","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0730","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0735","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0740","series-title":"Entresto [package insert]","year":"2015"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0745","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0750","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0755","first-page":"663","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0760","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","article-title":"Vasopeptidase inhibition and angio-oedema","volume":"356","author":"Messerli","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0765","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2015.01.033","article-title":"The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure","volume":"65","author":"Braunwald","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0770","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0775","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.amjcard.2015.09.029","article-title":"Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial)","volume":"116","author":"Bohm","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0780","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0785","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0790","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0795","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0800","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0805","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Authors","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0810","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0815","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0820","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0825","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0830","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0835","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0840","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0845","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0850","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0855","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0860","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0865","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0870","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0875","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0880","first-page":"35","article-title":"Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord","volume":"13","author":"Kapoor","year":"2013","journal-title":"Drug Targets"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0885","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0890","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.fjc.0000167013.77092.c4","article-title":"Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation","volume":"46","author":"Cleland","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0895","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/eurjhf\/hfp130","article-title":"The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure","volume":"11","author":"Klapholz","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0900","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2006.11.024","article-title":"Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial","volume":"49","author":"Ponikowski","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0905","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","article-title":"The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study","volume":"37","author":"Silverberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0910","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/hrt.2008.161091","article-title":"Erythropoietin treatment in patients with chronic heart failure: a meta-analysis","volume":"95","author":"van der Meer","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0915","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia","volume":"28","author":"van Veldhuisen","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0920","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","article-title":"Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia","volume":"117","author":"Ghali","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0925","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ahj.2011.02.013","article-title":"Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials","volume":"161","author":"Kotecha","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0930","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0935","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0940","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0945","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0950","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal\u00a0outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0955","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0960","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0965","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >\/=75 years: A randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0970","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1503\/cmaj.121468","article-title":"Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"185","author":"Lv","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0975","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure. a report of the American College of Cardiology Foundation\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0980","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","volume":"57","author":"Aronow","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0985","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0990","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9149(97)00320-2","volume":"80","author":"Aronow","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib0995","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1000","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1161\/CIRCULATIONAHA.110.012575","article-title":"Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"124","author":"Piller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1005","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1161\/CIRCULATIONAHA.106.683482","volume":"115","author":"Arzt","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1010","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa051001","article-title":"Continuous positive airway pressure for central sleep apnea and heart failure","volume":"353","author":"Bradley","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5664\/jcsm.27076","article-title":"The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers","volume":"4","author":"MacDonald","year":"2008","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJMoa1506459","article-title":"Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure","volume":"373","author":"Cowie","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2017.04.014_bib1030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ahj.2014.12.024","article-title":"Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"169","author":"Holmqvist","year":"2015","journal-title":"Am Heart J"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916417301070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916417301070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:03:08Z","timestamp":1601996588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916417301070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":205,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1071916417301070"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2017.04.014","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}